8QQ Stock Overview
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$4.49 |
| 52 Week Low | US$1.91 |
| Beta | 0.45 |
| 1 Month Change | -27.54% |
| 3 Month Change | -20.72% |
| 1 Year Change | -50.05% |
| 3 Year Change | -75.08% |
| 5 Year Change | n/a |
| Change since IPO | -93.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8QQ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.7% | -1.0% | -1.3% |
| 1Y | -50.0% | -17.5% | 13.1% |
Return vs Industry: 8QQ underperformed the German Life Sciences industry which returned -18.6% over the past year.
Return vs Market: 8QQ underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| 8QQ volatility | |
|---|---|
| 8QQ Average Weekly Movement | 11.7% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 8QQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8QQ's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 596 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. Fundamentals Summary
| 8QQ fundamental statistics | |
|---|---|
| Market cap | €672.05m |
| Earnings (TTM) | -€150.53m |
| Revenue (TTM) | €26.65m |
25.2x
P/S Ratio-4.5x
P/E RatioIs 8QQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8QQ income statement (TTM) | |
|---|---|
| Revenue | US$28.83m |
| Cost of Revenue | US$167.26m |
| Gross Profit | -US$138.43m |
| Other Expenses | US$24.43m |
| Earnings | -US$162.86m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.55 |
| Gross Margin | -480.10% |
| Net Profit Margin | -564.83% |
| Debt/Equity Ratio | 0% |
How did 8QQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 04:16 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbCellera Biologics Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Antonia Borovina | Bloom Burton & Co. |
| David Martin | Bloom Burton & Co. |